DexCom (FRA:DC4) Cyclically Adjusted PS Ratio: (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DC4 DexCom Inc FRA:DC4
92 GF Score
Price €64.40
GF Value €90.66
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is DexCom Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


DexCom  (FRA:DC4) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


DexCom Cyclically Adjusted PS Ratio Related Terms


DexCom Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for DexCom's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Cyclically Adjusted PS Ratio Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.32 32.52 28.31 14.46 10.20

DexCom Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.63 10.75 10.20 9.13 0.00

FRA:DC4 vs GEHC, STE, ZBH: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, DexCom's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DexCom's Cyclically Adjusted PS Ratio falls into.


FRA:DC4
92GF Score
DexCom Inc FRA:DC4
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

DexCom's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, DexCom's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.911/333.9520*333.9520
=2.911

Current CPI (Jun. 2026) = 333.9520.

DexCom Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.394 241.428 0.545
201612 0.480 241.432 0.664
201703 0.390 243.801 0.534
201706 0.434 244.955 0.592
201709 0.447 246.819 0.605
201712 0.537 246.524 0.727
201803 0.428 249.554 0.573
201806 0.580 251.989 0.769
201809 0.633 252.439 0.837
201812 0.836 251.233 1.111
201903 0.687 254.202 0.903
201906 0.817 256.143 1.065
201909 0.973 256.759 1.266
201912 1.125 256.974 1.462
202003 0.974 258.115 1.260
202006 1.034 257.797 1.339
202009 1.069 260.280 1.372
202012 1.177 260.474 1.509
202103 1.014 264.877 1.278
202106 1.156 271.696 1.421
202109 1.284 274.310 1.563
202112 1.432 278.802 1.715
202203 1.332 287.504 1.547
202206 1.563 296.311 1.762
202209 1.825 296.808 2.053
202212 1.806 296.797 2.032
202303 1.655 301.836 1.831
202306 1.864 305.109 2.040
202309 2.141 307.789 2.323
202312 2.274 306.746 2.476
202403 2.033 312.332 2.174
202406 2.238 314.175 2.379
202409 2.184 315.301 2.313
202412 2.615 315.605 2.767
202503 2.352 319.799 2.456
202506 2.458 322.561 2.545
202509 2.529 324.800 2.600
202512 2.697 324.054 2.779
202603 2.619 330.213 2.649
202606 2.911 333.952 2.911

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is DexCom (FRA:DC4) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of €64.40 is trading 29% below its estimated GF Value™ of €90.66. GuruFocus considers DexCom to be Modestly Undervalued.

Key valuation signals for FRA:DC4:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €90.66 vs. price of €64.40 (29% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the FRA:DC4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
92GF Score

Get the complete analysis for FRA:DC4

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.40
Price
€90.66
GF Value